Maze Therapeutics, Inc. (MAZE) Stock Score, Valuation & Financial Research

Maze Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MAZE

Maze Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 26.43. These figures are a research snapshot, not a buy or sell recommendation.

What Maze Therapeutics, Inc. does

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Maze Therapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through license agreements and research collaborations. The company utilizes its proprietary Compass platform to identify genetically validated targets and develop small molecule precision medicines for kidney and metabolic diseases.

Products and services

  • The company's pipeline includes MZE829, a dual-mechanism APOL1 inhibitor for APOL1-mediated kidney disease, and MZE782, an SLC6A19 inhibitor for phenylketonuria and chronic kidney disease.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its therapeutic candidates. Source

Business strengths to evaluate

  • Compass platform for genetic target identification Source

Business risks and research considerations

  • Intellectual property litigation and infringement claims Source
  • Dependence on third-party contract manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MAZE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 26.43
Market capitalization:
1.46B (currency not supplied)
Revenue:
USD 20M
Net income:
USD -133.59M
Free cash flow:
USD -112.73M
Cash:
USD 202.64M
Total debt:
USD 60.42M
EPS:
USD -2.74

What stands out

  • Free cash flow is USD -112.73M, negative for the stored period.
  • The balance sheet shows USD 202.64M of cash versus USD 60.42M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -563.7% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -668.0% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 142.22M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MAZE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MAZE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MAZE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MAZE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MAZE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MAZE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.